MENS - רווח נקי למניה (EPS TTM) Jyong Biotech Limited

The TTM earnings per share chart provided by the GURU.Markets platform demonstrates how AI is accelerating the development of men's health products. High certification and patent costs create a robust defensive moat for Jyong Biotech Ltd (MENS), while the -0.06 metric determines the status of the yield parameter. However, the lack of stable sales and stringent FDA requirements for botanical drugs create significant capital intensity risks.
Jyong Biotech Ltd (MENS) - פילוחי מדדים ודוחות פיננסיים

Analyzing EPS TTM is critical for constructing a defensive portfolio, as it measures the annual earnings per share and isolates financial results from the impact of share issuance volume. In the case of Jyong Biotech Ltd (MENS), this TTM net income per share slice reflects the efficiency of AI-driven drug synthesis against the backdrop of high costs for mandatory clinical trials.